Table 2 Key model inputs and assumptions Time ...

5 downloads 6540 Views 90KB Size Report
monotherapy. Laser monotherapy. Source. Year 1 BCVA progression RESTORE trial data, adjusted for drop-out rates. RESTORE trial data, adjusted for drop-out.
Table 2 Time

Key model inputs and assumptions Model input

Combination therapy

Ranibizumab

period Year 1

Laser monotherapy

Source

monotherapy BCVA progression RESTORE trial data,

RESTORE trial data,

RESTORE trial data,

adjusted for drop-out

adjusted for drop-out

adjusted for drop-out

rates

rates

rates

Treatment

7 injections + 2 laser

7 injections; drop-outs

2 laser sessions; drop-

frequency

sessions, as in

continue in standard

outs continue in

RESTORE; drop-outs

care (i.e. laser therapy)

standard care (i.e. laser

continue in standard

RESTORE data on file

RESTORE data on file

therapy)

care (i.e. laser therapy)

Year 2

Monitoring visits

12

12

4

Adverse events

Negligible

Negligible

Negligible

Equal rates of

Equal rates of

improvement and

improvement and

improvement and

worsening (3% in

worsening (3% in

worsening (3% in

3 months)

3 months)

3 months)

Treatment

2 injections + 1 laser

3 injections (no laser)

1 laser session

frequency

session

BCVA progression Equal rates of

SmPC and expert interview (data on file) RESTORE data on file Supported by DRCR.net and RESTORE data on file Supported by DRCR.net

Year 3

Any year

frequency

session

Monitoring visits

8

10

4

BCVA progression Constant rates of change Constant rates of change Constant rates of change of BCVA with a

of BCVA with a

of BCVA with a

majority of patients

majority of patients

majority of patients

having a decline in

having a decline in

having a decline in

BCVA

BCVA

BCVA

Treatment

No additional

No additional

Laser therapy as

frequency

ranibizumab; laser

ranibizumab; laser

required

therapy as required

therapy as required

Monitoring visits

4

4

Cost of blindness

When BCVA ≤35

When BCVA ≤35 letters When BCVA ≤35 letters

letters is reached in

is reached in better-

is reached in better-

better-seeing eye

seeing eye

seeing eye

4

Assumption Calibrated to WESDR data (Supplementary Methods)

Assumption

Assumption Adapted from costing approach by Meads et al.[16] (Supplementary Table 5)